The human gastric pathogen, Helicobacter pylori, colonizes more than 50% of the world population and is a well-known cause of peptic ulcer disease. H. pylori has been epidemiologically linked to various other diseases, among which its putative link with certain complex diseases such as type 1 diabetes mellitus (T1DM) is of interest. Although antibiotic resistance is a significant clinical problem in H. pylori infection control, the exact cause and much of the underlying mechanisms of T1DM are not clearly understood. In addition, commensal microflora, gut-adapted microbial communities, and plausible roles of some of the chronic human pathogens add an important dimension to the control of T1DM. Given this, the present review attempts to analyze and examine the confounding association of H. pylori and T1DM and the approaches to tackle them, and how the emerging field of vaccinomics might help in this pursuit.
Get full access to this article
View all access options for this article.
References
1.
AgarwalK., AgarwalS.2008. Helicobacter pylori vaccine: from past to future. Mayo Clinic Proc, 83:169–175.
2.
AkhianiA.A., SchonK., FranzenL.E., PappoJ., LyckeN.2004. H. pylori-specific antibodies impair the development of gastritis, facilitate bacterial colonization, and counteract resistance against infection. J Immunol, 172:5024–5033.
3.
AngelakopoulosH., HohmannE.L.2000. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun, 68:2135–2141.
4.
BackertS., SelbachM. 2008. Role of type IV secretion in Helicobacter pylori pathogenesis. Cell Microbiol, 10:1573–1581.
5.
BackertS., TegtmeyerN., SelbachM.2010. The versatility of Helicobacter pylori CagA effector protein functions: the master key hypothesis. Helicobacter, 15:163–176.
6.
BarrioR., RoldanM.B., AlonsoM., CantonR., CamareroC.1997. Helicobacter pylori infection with parietal cell antibodies in children and adolescents with insulin dependent diabetes mellitus. J Pediatr Endocrinol Metab, 10:511–516.
7.
BegueR.E., MirzaA., ComptonT., GomezR., VargasA.1999. Helicobacter pylori infection and insulin requirement among children with type 1 diabetes mellitus. Pediatrics, 103:e83.
8.
BenerA., MicallefR., AfifiM., DerbalaM., Al-MullaH.M., UsmaniM.A.2007. Association between type 2 diabetes mellitus and Helicobacter pylori infection. Turk J Gastroenterol, 18:225–229.
9.
BennisL.D., BoillotJ., BardinC., ZirinisP., CosteA., EscudierE.et al.2001. Six month administration of gelified intranasal insulin in 16 type 1 diabetic patients under multiple injections: efficacy vs subcutaneous injections and local tolerance. Diabetes Metab, 27:372–377.
10.
BlanchardT.G., EisenbergJ.C., MatsumotoY.2004. Clearance of Helicobacter pylori infection through immunization: the site of T cell activation contributes to vaccine efficacy. Vaccine, 22:888–897.
11.
BumannD., MetzgerW.G., MansouriE., PalmeO., WendlandM., HurwitzR.et al.2001. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine, 20:845–852.
12.
ChallacombeS.J., RahmanD., JefferyH., DavisS.S., O'HagenD.T.1992. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology, 76:164–168.
13.
ChinnS.J., NedrudJ.G.1999. Working towards a Helicobacter pylori vaccine. Gastroenterology, 116:990–993.
14.
Corthesy-TheulazI.E., HopkinsS., BachmannD., SaldingerP.F., PortaN., HaasR.et al.1998. Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits. Infect Immun, 66:581–586.
15.
CzinnS.J., NedrudJ.G.1991. Oral immunization against Helicobacter pylori. Infect Immun, 59:2359–2363.
16.
DasJ.C., PaulN.2007. Epidemiology and pathophysiology of Helicobacter pylori infection in children. Indian J Pediatr, 74:287–290.
17.
D'EliosM.M., AppelmelkB.J., AmedeiA., BergmanM.P., Del PreteG. 2004. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol Med, 10:316–323.
18.
DiPetrilloM.D., TibbettsT., KleanthousH., KilleenK.P., HohmanE.L.1999. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine, 18:449–459.
19.
DuboisA., BergD.E., IncecikE.T., FialaN., Heman-AckahL.M., Perez-PerezG.I.et al.1996. Transient and persistent experimental infection of nonhuman primates with Helicobacter pylori: implications for human disease. Infect Immun, 64:2885–2891.
20.
DuboisA., LeeC.K., FialaN., KleanthousH., MehlmanP.T., MonathT.1998. Immunization against natural Helicobacter pylori infection in nonhuman primates. Infect Immun, 66:4340–4346.
21.
ElsonC.O., EaldingW.1984. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol, 132:2736–2741.
22.
FerreroR.L., ThibergeJ.M., HuerreM., LabigneA.1994. Recombinant antigens prepared from the urease subunits of Helicobacter spp.: evidence of protection in a mouse model of gastric infection. Infect Immun, 62:4981–4989.
23.
FerreroR.L., ThibergeJ.M., KansauI., WuscherN., HuerreM., LabigneA.1995. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA, 92:6499–6503.
24.
FerreroR.L., ThibergeJ.M., LabigneA.1997. Local immunoglobulin G antibodies in the stomach may contribute to immunity against Helicobacter infection in mice. Gastroenterology, 113:185–194.
25.
FischerB., EliasD., BretzelR.G., LinnT.2010. Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes—an update. Expert Opin Biol Ther, 10:265–272.
26.
FranceschiF., GasbarriniA.2007. Helicobacter pylori and extragastric diseases. Best Pract Res Clin Gastroenterol, 21:325–334.
27.
GentaR.M.1997. The immunobiology of Helicobacter pylori gastritis. Semin Gastrointest Dis, 8:2–11.
28.
Gomez-DuarteO.G., LucasB., YanZ.X., PanthelK., HaasR., MeyerT.F.1998. Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine, 16:460–471.
29.
GottweinJ.M., BlanchardT.G., TargoniO.S., EisenbergJ.C., ZagorskiB.M., RedlineR.W.et al.2001. Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization. J Infect Dis, 184:308–314.
30.
HaN.C., OhS.T., SungJ.Y., ChaK.A., LeeM.H., OhB.H.2001. Supramolecular assembly and acid resistance of Helicobacter pylori urease. Nat Struct Biol, 8:505–509.
31.
HinkeS.A.2008. Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes. Curr Opin Mol Ther, 10:516–525.
32.
HoffelnerH., HaasR.2004. Recombinant bacterial ghosts: versatile targeting vehicles and promising vaccine candidates. Int J Med Microbiol, 294:303–311.
33.
HuppmannM., BaumgartenA., ZieglerA.G., BonifacioE.2005. Neonatal Bacille Calmette-Guerin vaccination and type 1 diabetes. Diabetes Care, 28:1204–1206.
34.
KavermannH., BurnsB.P., AngermullerK., OdenbreitS., FischerW., MelchersK.et al.2003. Identification and characterization of Helicobacter pylori genes essential for gastric colonization. J Exp Med, 197:813–822.
35.
KhalifaM.M., SharafR.R., AzizR.K.2010. Helicobacter pylori: a poor man's gut pathogen?Gut Pathogens, 2:2.
36.
KimS.Y., DohH.J., AhnJ.S., HaY.J., JangM.H., ChungS.I.et al.1999. Induction of mucosal and systemic immune response by oral immunization with H. pylori lysates encapsulated in poly (D,L-lactide-co-glycolide) microparticles. Vaccine, 17:607–633.
37.
LeeK.H., ChoM.J., YamaokaY., GrahamDY, YunYJ, WooSYet al.2004. Alanine-threonine polymorphism of Helicobacter pylori RpoB is correlated with differential induction of interleukin-8 in MKN45 cells. J Clin Microbiol, 42:3518–3524.
38.
LeunkR.D., JohnsonP.T., DavidB.C., KraftW.G., MorganD.R.1988. Cytotoxic activity in broth-culture filtrates of Campylobacter pylori. J Med Microbiol, 26:93–99.
39.
Londono-ArcilaP., FreemanD., KleanthousH., O'DowdA.M., LewisS., TurnerA.K.et al.2002. Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming–parenteral boosting vaccination regimen. Infect Immun, 70:5096–5106.
LudvigssonJ.2010. GAD-alum (Diamyd)—a new concept for preservation of residual insulin secretion. Expert Opin Biol Ther, 10:787–799.
42.
LyckeN., HolmgrenJ.1986. Intestinal mucosal memory and presence of memory cells in lamina propria and Peyer's patches in mice 2 years after oral immunization with cholera toxin. Scand J Immunol, 23:611–616.
43.
MalfertheinerP., SchultzeV., GiudiceG., RosenkranzB., KaufmannS.H.E., WinauF.et al.2002. Phase I safety and immunogenicity of a three-component H. pylori vaccine. Gastroenterology, 122,Suppl.1:A585.
44.
MaloyK.J., DonachieA.M., O'HaganD.T., MowatA.M.1994. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly (lactide-co-glycolide) microparticles. Immunology, 81:661–667.
OjettiV., PitoccoD., BartolozziF., DaneseS., MignecoA., LupascuA.et al.2002. High rate of Helicobacter pylori re-infection in patients affected by type 1 diabetes. Diabetes Care, 25:1485.
49.
OttemannK.M., LowenthalA.C.2002. Helicobacter pylori uses motility for initial colonization and to attain robust infection. Infect Immun, 70:1984–1990.
50.
OverberghL., DecallonneB., WaerM., RutgeertsO., ValckxD., CasteelsK.M.et al.2000. 1alpha, 25-dihydroxyvitamin D3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543)Diabetes, 8:1301–1307.
51.
PapamichaelK.X., PapaioannouG., KargaH., RoussosA., MantzarisG.J.2009. Helicobacter pylori infection and endocrine disorders: is there a link?World J Gastroenterol, 15:2701–2707.
52.
PappoJ., TorreyD., CastriottaL., SavinainenA., KabokZ., IbragimovA.1999. Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Infect Immun, 67:337–341.
53.
PolandG.A., OvsyannikovaI.G., JacobsonR.M., SmithD.I.2007. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther, 82:653–664.
54.
PolandG.A., OvsyannikovaI.G., JacobsonR.M.2008. Personalized vaccines: the emerging field of vaccinomics. Expert Opin Biol Ther, 8:1659–1667.
55.
RinaudoC.D., TelfordJ.L., RappuoliR., SeibK.L.2009. Vaccinology in the genome era. J Clin Invest, 119:2515–2525.
56.
RobinsonK., ArgentR.H., AthertonJ.C.2007. The inflammatory and immune response to Helicobacter pylori infection. Best Pract Res Clin Gastroenterol, 21:237–259.
57.
RossiG., RuggieroP., PeppoloniS., PancottoL., FortunaD., LaurettiL.et al.2004. Therapeutic vaccination against Helicobacter pylori in the Beagle Dog experimental model: safety, immunogenecity and efficacy. Infect Immun, 72:3252–3259.
58.
RyuS., KodamaS., RyuK., SchoenfeldD.A., FaustmanD.L.2001. Reversal of established autoimmune diabetes by restoration of endogenous β cell function. J Clin Invest, 108:63–72.
59.
SchalkJ.A., MooiF.R., BerbersG.A., van AertsL.A., OvelgonneH., KimmanT.G.2006. Preclinical and clinical safety studies on DNA vaccines. Hum Vaccines, 2:45–53.
60.
SeibK.L., DouganG., RappuoliR.2010. The key role of genomics in modern vaccine and drug design for emerging infectious diseases. PLOS Genet, 5:e1000612.
61.
SunB., LiZ.S., TuZ.X., XuG.M., DuY.Q.2006. Construction of an oral recombinant DNA vaccine from H pylori neutrophil activating protein and its immunogenicity. World J Gastroenterol, 12:7042–7046.
62.
SuttonP.2001. Progress in vaccination against Helicobacter pylori. Vaccine, 19:2286–2290.
TanahasiT., KitaM., KodamaT., YamaokaY., SawaiN., OhnoT.et al.2000. Cytokine expression and production by purified Helicobacter pylori urease in human gastric epithelial cells. Infect Immun, 68:664–671.
66.
ThomasC., MoridaniM.2009. Interindividual variations in the efficacy and toxicity of vaccines. Toxicology, 278:204–210.
67.
TigheH., CorrM., RomanM., RazE.1998. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today, 19:89–97.
68.
TsaiS., ShameliA., YamanouchiJ., Clemente-CasaresX., WangJ., SerraP.et al.2010. Reversal of autoimmunity by boosting memory-like autoregulatory T cells. Immunity, 32:568–580.
69.
VelinD., BachmannD., BouzoureneH., MichettiP.2005. Mast cells are critical mediators of vaccine-induced Helicobacter clearance in the mouse model. Gastroenterology, 129:142–155.
70.
WangG., WilsonT.J.M., JiangQ., TaylorD.E.2001. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother, 45:727–733.
71.
WotherspoonA.C., DoglioniC., DissT.C., PanL., MoschiniA., De BoniM.et al.1993. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet, 342:575–577.
72.
WyattJ.I., RathboneB.J., HeatleyR.V.1986. Local immune response to gastric Campylobacter in non-ulcer dyspepsia. J Clin Pathol, 39:863–870.
73.
XuC., LiZ.S., DuY.Q., GongY.F., YangH., SunB.et al.2007. Construction of recombinant attenuated Salmonella typhimurium DNA vaccine expressing H. pylori ureB and IL-2. World J Gastroenterol, 13:939–944.
